This session will explore how emerging AI technologies are transforming drug discovery and development through clinical care – from de novo drug design and target identification to clinical trial design and preventive care. Looking ahead to 2050, panelists will examine whether technologies such as AI, computational diagnostics, and digital health tools will accelerate R&D and expand access to personalized care or risk creating new digital and systemic barriers, particularly in resource-limited communities. The discussion will also focus on how companies are leveraging advances in AI today to foster discoveries of tomorrow.

PANELIST | Ángel Alberich-Bayarri, Ph.D., CEO & Co-founder, Quibim
PANELIST | Ilan Wapinski, Ph.D., Head of Digital in silico Research, Sanofi

Following the 2026 mid-term elections, what will dominate the policy conversations related to personalized medicine? Panelists will discuss potential implications for areas critical to supporting personalized medicine research, adoption, coverage, and reimbursement.

INTRODUCER | Mike Ybarra, M.D., Chief Medical Officer, PhRMA

PANELIST | Rachel Sher, J.D., MPH, Partner, Manatt, Phelps & Phillips, LLP
PANELIST | Priscilla VanderVeer, Executive Director, No Patient Left Behind
PANELIST | Jennifer F. Walsh, Director, Public Affairs, Foley & Lardner, LLP

As molecular diagnostics platforms generate increasingly large and complex datasets, AI is emerging as a powerful tool to support quality, interpretation, and clinical decision-making across disease areas, including immunology and rare disease. This panel discussion will explore how organizations across the personalized medicine ecosystem are using AI today to improve the analysis and usability of molecular and genomic data, while also addressing the validation, governance, and workflow considerations required for responsible implementation. This conversation will also focus on how AI can help translate complex diagnostic information into trusted, scalable insights that support better patient care and broader adoption of personalized medicine.

MODERATOR | Okan Ekinci, M.D., MBA, Global Head of Digital Technology & Chief Medical Information Officer, Roche Information Solutions, Roche Diagnostics

PANELIST | Michael Dunphy, M.D., Senior Director, International Business Lead for Data & Digital, Foundation Medicine, Inc.
PANELIST | Colin Hill, CEO & Co-founder, Aitia
PANELIST | Kate Sasser, Ph.D., Chief Scientific Officer, Tempus AI

PRESENTER | Lauren Silvis, J.D., Senior Vice President, External Affairs, Tempus

AWARDEE | Norman E. Sharpless, M.D., Professor of Cancer Policy and Innovation, University of North Carolina School of Medicine; 15th Director of the National Cancer Institute (2017-2022) and Former Acting Commissioner of the U.S. Food and Drug Administration (2019)

While oncology has driven many of the earliest breakthroughs in precision medicine, rapid advances in genomics, biomarker science, AI, digital health, and molecular diagnostics are now transforming care across a wide range of diseases and conditions. From cardiovascular and neurodegenerative diseases to autoimmune disorders, rare disease, infectious disease, and metabolic conditions, precision medicine is reshaping how conditions are identified, monitored, prevented, and treated.

This panel will explore how emerging technologies and scientific discoveries are enabling more personalized approaches far beyond cancer care. Panelists will discuss these new areas of impact, where scientific and implementation barriers remain, and key learnings from the application of precision approaches across disease states.

MODERATOR | Eric Mahoney, M.Sc., Associate Vice President, Science Policy and Research Programs, Personalized Medicine Coalition

PANELIST | Donna de Levante Raphael, Ph.D., Director of Research, Alzheimer’s Foundation of America
PANELIST | Terrie Livingston, PharmD, Vice President, Medical Affairs, Octave Bioscience, Inc.
PANELIST | Kristina McGuire, Ph.D., Executive Director and Head, Precision Medicine Laboratory Operations and Companion Diagnostics, Regeneron Pharmaceuticals

As precision medicine reshapes healthcare, the U.S. Food and Drug Administration plays a critical role in translating scientific innovation into safe, effective, and accessible patient care. This session will explore how regulatory frameworks are evolving to keep pace with advances in genomics, biomarkers, and targeted therapies. Panelists will discuss accelerated approvals, real-world evidence, evolving standards for evaluating personalized treatments, and the policy decisions shaping patient access to innovation. The discussion will also examine how the FDA can continue to support cutting-edge science while maintaining the rigorous standards that have been the steadfast guidepost that underpins public trust and patient safety globally.

MODERATOR | Lauren Silvis, J.D., Senior Vice President, External Affairs, Tempus

PANELIST | Namandjé N. Bumpus, Ph.D., Corporate Senior Vice President, Chief Scientific & Innovation Officer Charles River Laboratories; Former Principal Deputy Commissioner, U.S. Food and Drug Administration

PANELIST | Peter Marks, M.D., Ph.D., Senior Vice President, Molecule Discovery & Head of Infectious Disease Lilly Research Laboratories; Former Director, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration

PANELIST | Janet Woodcock, M.D., Former Principal Deputy Commissioner and Former Director, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration